Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E Millikan

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Seminars in Oncology|December 22, 1999
Chemotherapy of advanced prostatic carcinomaR E Millikan
Journal of the National Cancer Institute|July 22, 1998
Prospects for optimized clinical management of bladder cancer by application of phenotypic markersR E Millikan, C J Logothetis
Statistics in Medicine|May 3, 2000
Evaluating multiple treatment courses in clinical trialsP F Thall, R E Millikan, H G Sung
Cancer|July 10, 2001
Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicinR E Millikan, W K Plunkett, T L Smith, et al.
Gastroenterology|May 29, 2001
The bile acid-activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytesY Takikawa, H Miyoshi, C Rust, et al.
Cancer|December 10, 1997
Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinomaJ A Ellerhorst, A Sella, R J Amato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancerJ A Ellerhorst, S M Tu, R J Amato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2009
Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survivalA J Montero, C M Diaz-Montero, R E Millikan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancerS M Tu, L C Pagliaro, M E Banks, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2013
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapiesM R Matrana, C Duran, A Shetty, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Seminars in Oncology|December 22, 1999
Chemotherapy of advanced prostatic carcinomaR E Millikan
Journal of the National Cancer Institute|July 22, 1998
Prospects for optimized clinical management of bladder cancer by application of phenotypic markersR E Millikan, C J Logothetis
Statistics in Medicine|May 3, 2000
Evaluating multiple treatment courses in clinical trialsP F Thall, R E Millikan, H G Sung
Cancer|July 10, 2001
Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicinR E Millikan, W K Plunkett, T L Smith, et al.
Gastroenterology|May 29, 2001
The bile acid-activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytesY Takikawa, H Miyoshi, C Rust, et al.
Cancer|December 10, 1997
Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinomaJ A Ellerhorst, A Sella, R J Amato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancerJ A Ellerhorst, S M Tu, R J Amato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2009
Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survivalA J Montero, C M Diaz-Montero, R E Millikan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancerS M Tu, L C Pagliaro, M E Banks, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2013
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapiesM R Matrana, C Duran, A Shetty, et al.
Pageof 2